Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer

• المؤلفون الرئيسيون: Mok T.S., Geater S.L., Iannotti N., Thongprasert S., Spira A., Smith D., Lee V., Lim W.T., Reyderman L., Wang B., Gopalakrishna P., Garzon F., Xu L., Reynolds C.
• التنسيق: مقال
• اللغة: English
• منشور في: Oxford University Press 2014
• الوصول للمادة أونلاين: http://www.scopus.com/inward/record.url?eid=2-s2.0-84905162106&partnerID=40&md5=c014ad669a6469cce38f40b39d5fcc99; http://cmuir.cmu.ac.th/handle/6653943832/1781

Background: This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapies. Patients and methods: Eligible patients were randomized to eribulin mesy...